The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.


    Latest documents

    • Victor Levrague, Mario Alcocer-Ávila, Sarah Otmani, Lydia Maigne, Michael Beuve, et al.. Parametric modeling study of intracellular radionuclide distribution impact in Targeted Alpha Therapy. Symposium on Molecular Radiotherapy Dosimetry: The future of theragnostics, EFOMP, Nov 2023, AthĂšnes, GrĂšce, Greece. ⟨hal-04305428⟩
    • Yungan Tao, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, et al.. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European Journal of Cancer, 2023, 183, pp.24-37. ⟨10.1016/j.ejca.2022.12.015⟩. ⟨hal-04002440⟩
    • Anne-Sophie Wozny, Claire Rodriguez-Lafrasse. The ‘stealth-bomber’ paradigm for deciphering the tumour response to carbon-ion irradiation. British Journal of Cancer, 2023, 128, pp.1429-1438. ⟨10.1038/s41416-022-02117-6⟩. ⟨hal-03939645⟩
    • Hassan Abdoul-Carime, Janina Kopyra. Reactions in CCl4 films deposited onto a cold gold substrate induced by charge transfer vs (0–5) eV free electrons. Chem.Phys.Lett., 2023, 810, pp.140182. ⟨10.1016/j.cplett.2022.140182⟩. ⟨hal-03865746⟩
    • Wafa Bouleftour, Jean-Baptiste Guy, Pablo Moreno-Acosta, Claire Rodriguez Lafrasse, Paul Sargos, et al.. Challenges in radiobiology – technology duality as a key for a risk-free α/ÎČ ratio. Bulletin du Cancer, 2023, 110 (7-8), pp.768-775. ⟨10.1016/j.bulcan.2023.02.006⟩. ⟨hal-04170466⟩
    • Dietrich Averbeck. Low-Dose Non-Targeted Effects and Mitochondrial Control. Int.J.Mol.Sc., 2023, 24 (14), pp.11460. ⟨10.3390/ijms241411460⟩. ⟨hal-04178836⟩
    • Nicolas MagnĂ©, Elisabeth Daguenet, Wafa Bouleftour, Laurine Conraux, Fabien Tinquaut, et al.. Impact of Radiation Therapy on Biological Parameters in Cancer Patients: Sub-analysis from the RIT Prospective Epidemiological Study. Cancer Investigation, 2023, 41 (2), pp.109-118. ⟨10.1080/07357907.2022.2139838⟩. ⟨hal-03865012⟩
    • Janina Kopyra, Hassan Abdoul-Carime. Fragmentation of metal(II) bis(acetylacetonate) complexes induced by slow electrons. Beilstein J.Nanotechnol., 2023, 14, pp.980-987. ⟨10.3762/bjnano.14.81⟩. ⟨hal-04260493⟩
    • Brent Huisman, Enrique Muñoz, Denis Dauvergne, Jean Michel LĂ©tang, David Sarrut, et al.. Analytical modeling and Monte Carlo simulations of multi-parallel slit and knife-edge slit prompt gamma cameras. Physics in Medicine and Biology, 2023, 68 (11), pp.115009. ⟨10.1088/1361-6560/acd237⟩. ⟨hal-04100094⟩
    • Florence Charlieux, Hassan Abdoul‐carime. Processes Induced by Electrons at Sub‐Ionization Energies Studied by the Correlated Ions‐(Ions/Neutrals) Mass Spectrometry. ChemPhysChem, 2023, 24 (8), pp.e202200722. ⟨10.1002/cphc.202200722⟩. ⟨hal-03960242⟩
    • H Abdoul-Carime, F Mounier, F Charlieux, H AndrĂ©. Correlated ion-(ion/neutral) time of flight mass spectrometer. Rev.Sci.Instrum., 2023, 94 (4), pp.045104. ⟨10.1063/5.0141540⟩. ⟨hal-04088616⟩